FaDu In Vitro High Content Screening (HCS) Assay

This assay is to provide FaDu-based In Vitro High Content Screening (HCS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

FaDu

Human

FaDu is a cell line with epithelial morphology that was established in 1968 from a punch biopsy of a hypopharyngeal tumor removed from a 56-year-old, White, male patient with squamous cell carcinoma. This cell line is a suitable transfection host and has applications in cancer and immuno-oncology research.

Squamous Cell Carcinoma

Oncology

In Vitro High Content Screening (HCS) Assay

FaDu-cell based In Vitro High Content Screening (HCS) Assay

HCS is one of the latest techniques used in cancer drug discovery programs. Unlike traditional HTS platforms, HCS provides more visual information about the experiment being conducted. HCS is a very powerful tool for multivariate and quantitative data analysis. Cellbased HCS systems have also gained much attention in biological research and cancer drug discovery programs.

High-throughput Screening, High Content Screening and Reporter Gene Assays